Azadine-O (azacitidine oral) / Intas - LARVOL DELTA

Expert Point of View: Mikkael Sekeres, MD (THE ASCO POST) - "'Standard treatment of older or less fit adults with acute myeloid leukemia (AML) is now venetoclax/azacitidine, which has been shown to improve overall survival vs azacitidine monotherapy. Since that backbone was established, there has been a tsunami of trials looking at drugs added to this backbone,' said Mikkael Sekeres, MD..."

Media quote

Key Advances in Acute Myeloid Leukemia From ASH 2022 (Medscape) - "Dr Harry Erba...discusses his picks of the key advances in acute myeloid leukemia (AML) presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr Erba begins with three studies examining fundamental questions about the optimal induction regimen for newly diagnosed AML....Dr Erba then turns to two studies on venetoclax plus azacitidine in untreated AML."

Video

Intas Pharma launches oral Azacitidine for blood cancer patients (The Hindu Business Line) - "Intas Pharmaceuticals Ltd on Friday announced the launch of Azadine-O, an oral Azacitidine therapy for Acute Myeloid Leukemia (a type of blood cancer), a first for the Indian market. Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia."

Generic launch • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology